Twitter highlights from #ACR13 review course
/Juvenile Idiopathic Arthrits
Young children, and ANA are risks for uveitis for children in JIA, screen 3/12 in any children with pos ANA. Nigrovic #ACR13
— Philip Robinson (@philipcrobinson) October 26, 2013
The only acceptable outcome in the growing skeleton is remission (JIA) #ACR13 Nigrovic
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
Systemic Sclerosis
Not all hard skin = scleroderma. My favorite paper on scleroderma mimics: http://t.co/EiXaTGHyoE #ACR13
— Paul Sufka (@psufka) October 26, 2013
‘CREST’ diagnosis now Limited Cutaneous SSc. Centromere, Th/To Ab. GI, Lung (PAH, ILD), Digital Ulceres #acr13 Silver
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
Do not forget that patients with limited cutaneous SSc may develop PAH &ILD #ACR13
— Jose Campos (@JoseCamposMD) October 26, 2013
Greater than 15mg of prednisone risks scleroderma renal crisis Silver #ACR13
— Philip Robinson (@philipcrobinson) October 26, 2013
Rheumatic Disease and Pregnancy
Active SLE in pregnancy: 2x risk of preterm loss/preterm birth (3+ wks early). Try to have inactive 6 lupus 6mo before conception. #ACR13
— Paul Sufka (@psufka) October 26, 2013
HCQ may reduce risk of neonatal heart block in Lupus pregnancy #acr13 Clowse
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
Prevent pre term birth and preecamplisa maternal hypertension and low birth wt with ‘baby’ aspirin 81mg day #acr13 Clowse
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
TNF inhibitors have minimal transfer to breastmilk (not sure about colostrum) #ACR13
— Paul Sufka (@psufka) October 26, 2013
Psoriatic Arthritis
Next up: Psoriatic arthritis. Review of management from EULAR http://t.co/gq9PWjbRKG #ACR13
— Paul Sufka (@psufka) October 26, 2013
Obesity major risk factor for Ps arthritis, Obese PsA arthritis pts respond less well to anti TNF (Obesity ‘proinflammatory’). #acr13
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
Our episode of @TheRheumPodcast on the MIPA trial (methotrexate for PsA) http://t.co/ZVS4WhqVpm #ACR13
— Paul Sufka (@psufka) October 26, 2013
Osteoarthritis
We have a very effective treatment for OA, 38% patients obtaining little /no pain status: diet+exercise. But we want a magic drug... #ACR13
— Jose Campos (@JoseCamposMD) October 26, 2013
Erosive OA w/ palpable inflammation may respond to adalimumab. Limited data though. We often try HCQ, but ineffective. #ACR13
— Paul Sufka (@psufka) October 26, 2013
Opioids
Opioid prescribing increased 400%in last 10 years. Wallace #acr13
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
“Although the US is the number 1 consumer of opioids in the world, there is no evidence that pain outcomes are better” #ACR13
— Paul Sufka (@psufka) October 26, 2013
Morbidity from DMARDs
Guidelines on use of DMARDs (PDF): http://t.co/NZf2VkuTqp #ACR13
— Paul Sufka (@psufka) October 26, 2013
Rituximab more appropriate than anti TNF for RA if malignancy in last 5 years #acr13 Bingham III
— Dr. Ronan Kavanagh (@RonanTKavanagh) October 26, 2013
Ok to give zoster vaccine: prednisone <20mg/day or short course <2wk, methotrexate (at our typical doses), azathioprine/6MP #ACR13
— Paul Sufka (@psufka) October 26, 2013
